Compare VanEck Gold Miners ETF (GDX) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Gold Miners ETF vs 10X Genomics Inc — how do they compare? VanEck Gold Miners ETF trades at $89.01 (market cap $25.65B), while 10X Genomics Inc trades at $80.53 (market cap $10.07B). The key difference: VanEck Gold Miners ETF is far larger — about 2.5× 10X Genomics Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, VanEck Gold Miners ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Gold Miners ETF for 76 Days and 10X Genomics Inc for 92 Days on average.
| GDX | TXG | |
|---|---|---|
Market Cap | $25.65B | $10.07B |
Volume | 16,534,046 | 5,657,286 |
52-Week High | $115.84 | $97.74 |
52-Week Low | $68.28 | $11.48 |
Typical Hold Time | 76 Days | 92 Days |
Sector | — | Health |
Enterprise Value | — | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDX trades at $89.31, up 4.51% over the past 24 hours, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF faces headwinds from rising interest rates pressuring dividend stocks and a recent sell-off in metals. Support levels are clustered between $84 and $86, while resistance sits near $87 to $89. Recent news highlights institutional selling by firms like Allworth Financial and HB Wealth Management, though Ameritas Advisory Services increased its stake.
The outlook for GDX is cautious due to bearish technicals and macroeconomic pressures on gold miners. Opportunities exist if gold prices rebound, but risks include persistent rate hikes and volatility in commodity markets. Investors should weigh the ETF's leverage to gold against operational risks in the mining sector.
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Gold Miners ETF
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
